US AEROSOL CANS MARKET

INTRODUCTION

A steady aerosol of the substance is produced by the propellant, which also aids in maintaining constant or almost constant pressure. In order to release the product from an aerosol can, internal pressure is used as the dispersal method. In order to force the product or active chemicals out of the can, the aerosol can propellant is added to the can to produce internal pressure. Without a propellant, the spray would gradually lessen as the can was consumed and its internal pressure dropped until it was equal to the atmosphere outside the can, at which point it would stop totally. 

Some aerosol cans employ a compressed gas as their propellant, such as nitrogen or carbon dioxide.Compressed gas has the advantage of being extremely affordable and non-flammable, whereas other ingredients in the aerosol can be. The drawback of using compressed gas as an aerosol can propellant is that it will cause the can's internal pressure to drop over time. The pressure inside the can falls as the product inside is used, which results in a decrease in the can's dispersing power. If a propellant weren't employed, the spray would eventually stop completely after the can's internal pressure was equal as the can was consumed and its pressure reduced. 

US AEROSOL CANS MARKET  SIZE AND FORECAST

 The US aerosol cans market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

NEW PRODUCT LAUNCH

 In a single, simple-to-use nasal spray, RYALTRIS is the only fixed-dose combination medication that relieves both ocular and nasal symptoms of seasonal allergic rhinitis. In the US, RYALTRIS is a nasal spray formulation of olopatadine hydrochloride and mometasone furoate. The US Food and Drug Administration has approved RYALTRIS for the treatment of seasonal allergic rhinitis symptoms in adult and pediatric patients 12 years of age and older. This launch enhances Hikma's goal of expanding its specialized business in the US and builds on the company's dominant position as one of the biggest US suppliers of nasally given medications used to treat seasonal allergies. The only fixed-dose combination medication, RYALTRIS, relieves both nasal and ocular SAR symptoms in a single, simple-to-use nasal spray. 

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many aerosol cans are manufactured per annum in US? Who are the sub-component suppliers in different regions?
2. Cost breakup of a US aerosol cans and key vendor selection criteria
3. Where is the aerosol cans manufactured? What is the average margin per unit?
4. Market share of US aerosol cans market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture US aerosol cans in-house
6. key predictions for next 5 years in US aerosol cans market
7. Average B-2-B aerosol cans market price in all segments
8. Latest trends in aerosol cans market, by every market segment
9. The market size (both volume and value) of the aerosol cans market in 2023-2030 and every year in between?
10. Production breakup of aerosol cans market, by suppliers and their OEM relationship